MSK-MIND Lung Cancer Multimodal 2020

Overview

The MSK-MIND (Multimodal Integration of Imaging, pathology aND genomics) dataset from Memorial Sloan Kettering Cancer Center comprises 247 patients with advanced non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade between 2014 and 2019. The cohort integrates baseline CT radiomics, digitized PD-L1 immunohistochemistry texture features, and MSK-IMPACT genomic data to support multimodal immunotherapy response prediction. Dataset deposited in cBioPortal as lung_msk_mind_2020.

Composition

  • 247 patients with advanced NSCLC treated with PD-(L)1 blockade at MSK, 2014–2019.
  • Histology: 79% adenocarcinoma (LUAD), 15% squamous (LUSC), 3% large cell, 3% NSCLC NOS.
  • Response binarized as responders (CR/PR, 25%) vs. nonresponders (SD/PD, 75%) per RECIST v1.1.
  • Median PFS 2.7 months (95% CI 2.5–3.0); median OS 11.4 months (95% CI 10.3–12.8).
  • Additional hold-out cohorts: radiology validation (n = 50), pathology validation (n = 52).

Assays / panels (linked)

  • MSK-IMPACT — targeted genomic sequencing; TMB median 7 mt/Mb (range 0–90)
  • CT radiomics — baseline CT scan lesion segmentation and feature extraction
  • PD-L1 IHC — digitized whole-slide images; texture feature extraction (IHC-G) and pathologist-scored TPS

Papers using this cohort

  • PMID:36038778 — Primary analysis using DyAM multimodal ML model for PD-(L)1 blockade response prediction in advanced NSCLC.

Notable findings derived from this cohort

  • The DyAM multimodal model integrating CT radiomics, PD-L1 IHC texture features, and MSK-IMPACT genomic data achieved AUC = 0.80 (95% CI 0.74–0.86), significantly outperforming all unimodal approaches including TMB alone (AUC = 0.61) and PD-L1 TPS alone (AUC = 0.73) PMID:36038778.
  • STK11 mutation (17.8% of cohort) and EGFR mutation (8.9%) were independently associated with worse immunotherapy outcomes on multivariate analysis (STK11: aHR = 2.53, p < 0.005; EGFR: aHR = 2.14, p = 0.03); higher TMB was independently associated with better outcomes (aHR = 0.14, p = 0.04) PMID:36038778.
  • Multimodal DyAM risk stratification separated high- and low-risk patients significantly: progression at 4 months was 21% for the lowest (protective) quartile vs. 79% for the highest (risk) quartile PMID:36038778.

Sources

  • cBioPortal study: lung_msk_mind_2020

This page was processed by crosslinker on 2026-05-06.